addition, costs have been shown to be significantly higher due in part to the need for continued follow-up and higher reintervention rates of around 16%. When NICE did their costings using data from the ACE, DREAM and EVAR trials, the incremental cost-effectiveness ratio (ICER) was between £48,990 and 2.8 million per quality of life gain (QALY). The OVER trial was the only study assessed in isolation to show the potential to meet the £20,000 per QALY threshold with a high probability of 91% [5] . NICE's calculations, however, using all the available trials data, showed a\ 1% probability of achieving this.
Proponents of EVAR argue that the trial data are historical and that both contemporary practice and today's devices have improved sufficiently to make the outcomes mentioned above obsolete. The appreciation of the need for a more proximal seal zone, a reduction in intervention for all type II endoleaks and moving to duplex surveillance may have an impact, but to date there is no high level evidence to support such claims. This has led to the recent controversial draft NICE guidelines on AAA management, where EVAR is no longer recommended for unruptured aneurysms and only in the context of research studies for juxta-renal or supra-renal aneurysms. NICE guidelines are highly valued and respected throughout the world so although this so far has only been released for consultation, it has resulted in a huge impact and major negative response from the world medical community.
Even if published in an unabridged form, most feel that implementation would be difficult. EVAR is a mature treatment within all vascular units in the local aortic networks (LANs) in the united kingdom (UK). Patients have embraced the minimally invasive advantages with faster recovery times. Despite there being patient representation on the NICE board, there is a feeling that the recommendations in their current form do not take account of patient choice and the greater importance an elderly population attaches to early benefit compared with what might happen in a decade's time. In a world where global information is available instantly, patients will no doubt feel they are entitled to at least consider treatment modalities, not only available, but often recommended as first choice in most European countries, Australia and the United states of America (USA). Counterintuitively, the draft NICE guidelines recommend EVAR as an option for emergency treatment in rupture patients (based on the IMPROVE results) which clearly would be difficult if operators no longer have experience of elective cases and potentially the full range of equipment necessary for all situations. The impact on hospital capacity also has to be considered. Many struggle with both hospital bed and critical care capacity, and the conversion of a proportion of AAA patients from EVAR to open surgery is likely to impact significantly on length of stay and critical care bed usage. Moreover, the UK AAA national screening programme (NAAASP) may also be at risk. Already, up to 20% of screen-detected AAA patients do not undergo intervention, mostly as a result of fitness. If this was increased further (inevitable if open surgery is the only treatment option), the utility, not to mention the cost-effectiveness of the NAAASP would have to be reconsidered.
Many of us of course still believe that EVAR has a major role still to play in the treatment of abdominal aortic aneurysms, but now appreciate that this cannot apply to all patients. However, as clinicians, we have failed to identify the cohort that will benefit long term. It is extremely unlikely that we will be able to set up another randomised trial for EVAR and even if we could, it would take a decade or more to produce meaningful results to satisfy durability concerns. Instead, we need to urgently review what we have in terms of published data to show which groups we believe will benefit from EVAR. The UK National Vascular Registry (NVR) was designed to report early outcomes and more recently provide information to support the NHS directed need for individual surgeon outcome data in the public domain. Most would now agree that 30 day mortality figures of 1-2% make such outcome measures less relevant and we need to look at longitudinal data over the duration of a patient's life to gain a better insight into durability. Although possible, this is far more resource heavy and expensive, but clearly now necessary.
Whether we accept the NICE draft guidelines or not, there are some valuable lessons to take on board. The peak of EVAR exuberance has probably passed, at least for the current device iteration, and its continued use must be tempered to take account of durability. We need to ensure that training still reflects a future (at least for now) need for open surgery for some patients and accept that such procedures will be technically more difficult. Further centralisation and the proposed LANs may facilitate this. We also need to identify those patients who will not benefit from treatment either because of limited life expectancy or because of comorbidities. Although clearly sensible on a population basis, this is harder to apply to an individual patient and we will need to develop strategies to manage patient expectations and concerns.
Longer term we need to re-evaluate the EVAR concept. The goal is to prevent or effectively treat acute aneurysm rupture with minimal harm to the patient. Certainly, re-lining the aorta with a prosthetic introduced endoluminally remains a very attractive option and is likely to be the way forward, but the current strategy of fixation and radial force without sac management is unlikely to improve outcomes in adverse anatomy. The majority of devices currently available are developments of this original concept and the one deviation away from it (using polymer filled bags in the aneurysm sac) was found wanting. Future devices will need to change and adapt to our knowledge of neck dilatation and changes within the sac overtime. The drive should be towards ideally obliteration of the space within the aortic sac rather than with sac size stability.
In conclusion this is not the end for EVAR-there are patient groups that will benefit with today's technology and we have to identify them and continue to monitor them for effectiveness and durability. Crucially, this will enable continued research and development to produce the next iteration of the EVAR concept that will hopefully address some of the current inadequacies. The future may well be endovascular, but it is not yet clear when that will be. In the interim, we need to ensure we have surgeons who can still continue to operate in these challenging patients.
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